| Vol. 22.10 – 22 March, 2021 |
| |
|
|
| Scientists showed that myogenic stem cells—which were selectively expanded from readily obtainable dermal fibroblasts or skeletal muscle stem cells using a specific cocktail of small molecules and transplanted into muscle injuries in adult, aged or dystrophic mice—led to functional muscle regeneration in the three animal models. [Nature Biomedical Engineering] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Linc00402 was increased in donor T cells from patients who underwent allogeneic cardiac transplantation and in murine T cells. [Science Translational Medicine] |
|
|
|
| Scientists developed a wound dressing material based on an integrated photo-crosslinking strategy and a microcapsule platform with pulsatile release of TGF-β inhibitor to achieve spatiotemporal specificity for skin wounds. [Nature Communications] |
|
|
|
| Researchers hypothesized that a single administration of an adeno‐associated virus coding for an anti‐eosinophil monoclonal antibody that induces eosinophil clearance would treat on a persistent basis a murine model of eosinophilic esophagitis. [Allergy] |
|
|
|
| To explore cell replacement therapies as a possible approach to treat Friedreich ataxia (FRDA), scientists examined transplantation of sensory neural progenitors derived from human embryonic stem cells and FRDA induced pluripotent stem cells (iPSCs) into adult rodent dorsal root ganglia regions. [Stem Cells Translational Medicine] |
|
|
|
| Researchers investigated the feasibility and safety of MRI-guided transplantation of glial restricted precursors and mesenchymal stem cells in dogs suffering from ALS-like disease, degenerative myelopathy. [Scientific Reports] |
|
|
|
| Scientists created the fourth-generation CAR construct containing anti-MUC1-single-chain variable fragment and three co-stimulatory domains linked to CD3ζ and evaluated anti-MUC1-CAR4 T cells in cholangiocarcinoma models. [Scientific Reports] |
|
|
|
| The authors assessed the therapeutic potential of co-administration of human clonal mesenchymal stem cells and liraglutide as a glucagon-like peptide-1 agonist in a non-human primate model with streptozotocin-induced diabetes. [Life Sciences] |
|
|
|
| Investigators evaluated the bone regeneration potential of nanohydroxyapatite/chitosan/gelatin three-dimensional porous scaffold with human periodontal ligament stem cells in critical-sized jaw bone defects in minipigs. [Stem Cells and Development] |
|
|
|
|
| Investigators provide an overview of contributions to gene therapy made by German clinical and research institutions. [Gene Therapy] |
|
|
|
| The authors take a closer look at the commercial CAR-T cell therapies, as well as on CAR-T and CAR-NK cell products, which are currently under evaluation in clinical trials that are being conducted in Germany. [Gene Therapy] |
|
|
|
|
| Sangamo Therapeutics, Inc. announced that the European Medicines Agency’s Committee for Orphan Medicinal Products released details supporting the Orphan Designation of BIVV003, an investigational ex vivo gene-edited cell therapy product candidate currently being evaluated for the treatment of sickle cell disease in the Phase I/II PRECIZN-1 study partnered with Sanofi. [Sangamo Therapeutics, Inc.] |
|
|
|
| Anixa Biosciences, Inc. announced that an IND (Investigational New Drug) application for its ovarian cancer CAR-T therapy has been filed with the FDA. [Anixa Biosciences, Inc.] |
|
|
|
| Rocket Pharmaceuticals, Inc. announced updated preliminary clinical data from its Phase I trial of RP-L301 for the treatment of Pyruvate Kinase Deficiency, showing durable normalization of hemoglobin levels up to six months following therapy and similar three-month trends in the second patient treated. [Rocket Pharmaceuticals, Inc.] |
|
|
|
| Celularity, Inc. announced that the company has received Fast Track Designation from the FDA for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, CYNK-001, for the treatment of adults with recurrent glioblastoma multiforme. [Celularity, Inc.] |
|
|
|
|
| April 6 – 9, 2021 Virtual |
|
|
|
|
|
| NIH National Institute of Allergy and Infectious Diseases – Bethesda, Maryland, United States |
|
|
|
| The University of Iowa – Iowa City, Iowa, United States |
|
|
|
| Gladstone Institute – San Francisco, California, United States |
|
|
|
| National University of Ireland Galway – Galway, Ireland |
|
|
|
| Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
|